We explored the feasibility of intraperitoneal (IP) delivery of vvDD-IL15/Rα to promote peritoneal memory, tumor-antigen-specific T cells with enhanced anti-tumor effector function, suitable for ACT in murine syngeneic and immunocompetent models of colorectal and pancreatic cancers. Here, IL15 is linked to neoplasm.